Pipeline

Acute Myeloïd Leukemia

ODYSSEY

ODYSSEY is a Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML). It is a multicenter study, with centers in Paris, Lyon and Marseille, designed to assess the safety and tolerability of the drug candidate ABD-3001 (NCT05601726).

Following an adaptive design, the study integrates an ascending single-dose first part, on six patient cohorts, followed by a second part, which three regimens will be tested during three months.

Fully funded by Advanced BioDesign, the ODYSSEY clinical trial is coordinated by Professor Régis COSTELLO (Hôpital de la Conception, Marseille), in collaboration with Doctor Lina BENAJIBA (Hôpital Saint-Louis, Paris), and Doctor Maël HEIBLIG (Hôpital Lyon Sud, Lyon).